54 related articles for article (PubMed ID: 30092367)
1. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
[TBL] [Abstract][Full Text] [Related]
2. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
[TBL] [Abstract][Full Text] [Related]
3. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Li X; Peterson YK; Inks ES; Himes RA; Li J; Zhang Y; Kong X; Chou CJ
J Med Chem; 2018 Mar; 61(6):2589-2603. PubMed ID: 29499113
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors.
Campiani G; Cavella C; Osko JD; Brindisi M; Relitti N; Brogi S; Saraswati AP; Federico S; Chemi G; Maramai S; Carullo G; Jaeger B; Carleo A; Benedetti R; Sarno F; Lamponi S; Rottoli P; Bargagli E; Bertucci C; Tedesco D; Herp D; Senger J; Ruberti G; Saccoccia F; Saponara S; Gorelli B; Valoti M; Kennedy B; Sundaramurthi H; Butini S; Jung M; Roach KM; Altucci L; Bradding P; Christianson DW; Gemma S; Prasse A
J Med Chem; 2021 Jul; 64(14):9960-9988. PubMed ID: 34251197
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel HDAC inhibitors with a 3-(benzazol-2-yl)quinoxaline framework.
Yang Y; Liu Q; Wang X; Gou S
Bioorg Med Chem Lett; 2023 May; 88():129305. PubMed ID: 37116762
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups.
Han B; Gu X; Wang M; Wang H; Sun N; Yang X; Zhang Q
Chem Biol Drug Des; 2024 May; 103(5):e14556. PubMed ID: 38772881
[TBL] [Abstract][Full Text] [Related]
8. The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production.
Hsu TJ; Nepali K; Tsai CH; Imtiyaz Z; Lin FL; Hsiao G; Lai MJ; Cheng YW
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299636
[TBL] [Abstract][Full Text] [Related]
9. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia.
Zhang K; Huang R; Ji M; Lin S; Lai F; Wu D; Tian H; Bi J; Peng S; Hu J; Sheng L; Li Y; Chen X; Xu H
Eur J Med Chem; 2024 Jan; 264():116015. PubMed ID: 38048697
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Histone Deacetylase Inhibitors Derived from Erianin and Its Derivatives.
Yang Y; Liu Q; Wang X; Gou S
ChemMedChem; 2023 Jul; 18(13):e202300108. PubMed ID: 37058395
[TBL] [Abstract][Full Text] [Related]
11. Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells.
Ononye SN; Vanheyst MD; Giardina C; Wright DL; Anderson AC
Bioorg Med Chem; 2014 Apr; 22(7):2188-93. PubMed ID: 24613456
[TBL] [Abstract][Full Text] [Related]
12. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents.
Waitman KB; de Almeida LC; Primi MC; Carlos JAEG; Ruiz C; Kronenberger T; Laufer S; Goettert MI; Poso A; Vassiliades SV; de Souza VAM; Toledo MFZJ; Hassimotto NMA; Cameron MD; Bannister TD; Costa-Lotufo LV; Machado-Neto JA; Tavares MT; Parise-Filho R
Eur J Med Chem; 2024 Jan; 263():115935. PubMed ID: 37989057
[TBL] [Abstract][Full Text] [Related]
13. Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents.
Papa A; Cursaro I; Pozzetti L; Contri C; Cappello M; Pasquini S; Carullo G; Ramunno A; Gemma S; Varani K; Butini S; Campiani G; Vincenzi F
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300410. PubMed ID: 37750286
[TBL] [Abstract][Full Text] [Related]
14. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Kollar J; Frecer V
J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
[TBL] [Abstract][Full Text] [Related]
16. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.
Relitti N; Saraswati AP; Chemi G; Brindisi M; Brogi S; Herp D; Schmidtkunz K; Saccoccia F; Ruberti G; Ulivieri C; Vanni F; Sarno F; Altucci L; Lamponi S; Jung M; Gemma S; Butini S; Campiani G
Eur J Med Chem; 2021 Feb; 212():112998. PubMed ID: 33199154
[TBL] [Abstract][Full Text] [Related]
17. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.
Curcio A; Rocca R; Alcaro S; Artese A
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794190
[TBL] [Abstract][Full Text] [Related]
18. Exploration of Structure-Activity Relationship Using Integrated Structure and Ligand Based Approach: Hydroxamic Acid-Based HDAC Inhibitors and Cytotoxic Agents.
Shirbhate E; Pandey J; Patel VK; Veerasamy R; Rajak H
Turk J Pharm Sci; 2023 Aug; 20(4):270-284. PubMed ID: 37606012
[TBL] [Abstract][Full Text] [Related]
19. Diastereoselective Synthesis of
Lindman J; Gopalan G; Palo-Nieto C; Brandt P; Gising J; Larhed M
ACS Omega; 2022 Sep; 7(36):32525-32535. PubMed ID: 36120037
[TBL] [Abstract][Full Text] [Related]
20. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
